Nam Hoon Kim, Mi-Hae Seo, Jin Hyung Jung, Kyung Do Han, Mi Kyung Kim, Nan Hee Kim, on Behalf of Diabetic Kidney Disease Research Group of the Korean Diabetes Association
Received July 30, 2023 Accepted January 26, 2024 Published online March 19, 2024
Background To investigate the prevalence, incidence, comorbidities, and management status of diabetic kidney disease (DKD) and diabetes-related end-stage kidney disease (ESKD) in South Korea.
Methods We used the Korea National Health and Nutrition Examination Survey data (2019 to 2021, n=2,665) for the evaluation of prevalence, comorbidities, control rate of glycemia and comorbidities in DKD, and the Korean Health Insurance Service-customized database (2008 to 2019, n=3,950,857) for the evaluation of trends in the incidence and prevalence rate of diabetes-related ESKD, renin-angiotensin system (RAS) blockers and sodium glucose cotransporter 2 (SGLT2) inhibitors use for DKD, and the risk of atherosclerotic cardiovascular disease (ASCVD) and mortality according to DKD stages. DKD was defined as albuminuria or low estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 in patients with diabetes mellitus.
Results The prevalence of DKD was 25.4% (albuminuria, 22.0%; low eGFR, 6.73%) in patients with diabetes mellitus aged ≥30 years. Patients with DKD had a higher rate of comorbidities, including hypertension, dyslipidemia, and central obesity; however, their control rates were lower than those without DKD. Prescription rate of SGLT2 inhibitors with reduced eGFR increased steadily, reaching 5.94% in 2019. Approximately 70% of DKD patients were treated with RAS blockers. The prevalence rate of diabetesrelated ESKD has been steadily increasing, with a higher rate in older adults. ASCVD and mortality were significantly associated with an in increase in DKD stage.
Conclusion DKD is prevalent among Korean patients with diabetes and is an independent risk factor for cardiovascular morbidity and mortality, which requiring intensive management of diabetes and comorbidities. The prevalence of diabetes-related ESKD has been increasing, especially in the older adults, during past decade.
Citations
Citations to this article as recorded by
Endothelial NOX5 Obliterates the Reno-Protective Effect of Nox4 Deletion by Promoting Renal Fibrosis via Activation of EMT and ROS-Sensitive Pathways in Diabetes Karin A. M. Jandeleit-Dahm, Haritha R. Kankanamalage, Aozhi Dai, Jaroslawna Meister, Sara Lopez-Trevino, Mark E. Cooper, Rhian M. Touyz, Christopher R. J. Kennedy, Jay C. Jha Antioxidants.2024; 13(4): 396. CrossRef
Ye Seul Yang, Nam Hoon Kim, Jong Ha Baek, Seung-Hyun Ko, Jang Won Son, Seung-Hwan Lee, Sang Youl Rhee, Soo-Kyung Kim, Tae Seo Sohn, Ji Eun Jun, In-Kyung Jeong, Chong Hwa Kim, Keeho Song, Eun-Jung Rhee, Junghyun Noh, Kyu Yeon Hur, Committee of Clinical Practice Guidelines, Korean Diabetes Association
Diabetes Metab J. 2024;48(2):279-289. Published online January 26, 2024
Background Recent diabetes management guidelines recommend that sodium-glucose cotransporter 2 inhibitors (SGLT2is) or glucagon-like peptide 1 receptor agonists (GLP-1RAs) with proven cardiovascular benefits should be prioritized for combination therapy in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD). This study was aimed at evaluating SGLT2i or GLP-1RA usage rates and various related factors in patients with T2DM and established CVD.
Methods We enrolled adults with T2DM aged ≥30 years who were hospitalized due to established CVD from January 2019 to May 2020 at 13 secondary and tertiary hospitals in Korea in this retrospective observational study.
Results Overall, 2,050 patients were eligible for analysis among 2,107 enrolled patients. The mean patient age, diabetes duration, and glycosylated hemoglobin level were 70.0 years, 12.0 years, and 7.5%, respectively. During the mean follow-up duration of 9.7 months, 25.7% of the patients were prescribed SGLT2is after CVD events. However, only 1.8% were prescribed GLP-1RAs. Compared with SGLT2i non-users, SGLT2i users were more frequently male and obese. Furthermore, they had a shorter diabetes duration but showed worse glycemic control and better renal function at the time of the event. GLP-1RA users had a longer duration of diabetes and worse glycemic control at the time of the event than GLP-1RA non-users.
Conclusion The SGLT2i or GLP-1RA prescription rates were suboptimal in patients with T2DM and established CVD. Sex, body mass index, diabetes duration, glycemic control, and renal function were associated with the use of these agents.
Citations
Citations to this article as recorded by
Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD Gwanpyo Koh Diabetes & Metabolism Journal.2024; 48(2): 208. CrossRef
Da Young Lee, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Nan Hee Kim
Diabetes Metab J. 2024;48(1):37-52. Published online January 3, 2024
Novel strategies are required to reduce the risk of developing diabetes and/or clinical outcomes and complications of diabetes. In this regard, the role of the circadian system may be a potential candidate for the prevention of diabetes. We reviewed evidence from animal, clinical, and epidemiological studies linking the circadian system to various aspects of the pathophysiology and clinical outcomes of diabetes. The circadian clock governs genetic, metabolic, hormonal, and behavioral signals in anticipation of cyclic 24-hour events through interactions between a “central clock” in the suprachiasmatic nucleus and “peripheral clocks” in the whole body. Currently, circadian rhythmicity in humans can be subjectively or objectively assessed by measuring melatonin and glucocorticoid levels, core body temperature, peripheral blood, oral mucosa, hair follicles, rest-activity cycles, sleep diaries, and circadian chronotypes. In this review, we summarized various circadian misalignments, such as altered light-dark, sleep-wake, rest-activity, fasting-feeding, shift work, evening chronotype, and social jetlag, as well as mutations in clock genes that could contribute to the development of diabetes and poor glycemic status in patients with diabetes. Targeting critical components of the circadian system could deliver potential candidates for the treatment and prevention of type 2 diabetes mellitus in the future.
Background To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM).
Methods This study was a randomized, multicenter, open, parallel phase 4 study, and enrolled T2DM subjects with an estimated 10-year ASCVD risk ≥7.5%. The primary endpoint was the low-density lipoprotein cholesterol (LDL-C) change rate after 24-week rosuvastatin 10 mg/ezetimibe 10 mg treatment was non-inferior to that of rosuvastatin 20 mg. The achievement proportion of 10-year ASCVD risk <7.5% or comprehensive lipid target (LDL-C <70 mg/dL, non-high-density lipoprotein cholesterol <100 mg/dL, and apolipoprotein B <80 mg/dL) without discontinuation, and several metabolic parameters were explored as secondary endpoints.
Results A hundred and six participants were assigned to each group. Both groups showed significant reduction in % change of LDL-C from baseline at week 24 (–63.90±6.89 vs. –55.44±6.85, combination vs. monotherapy, p=0.0378; respectively), but the combination treatment was superior to high-intensity monotherapy in LDL-C change (%) from baseline (least square [LS] mean difference, –8.47; 95% confidence interval, –16.44 to –0.49; p=0.0378). The combination treatment showed a higher proportion of achieved comprehensive lipid targets rather than monotherapy (85.36% vs. 62.22% in monotherapy, p=0.015). The ezetimibe combination significantly improved homeostasis model assessment of β-cell function even without A1c changes (LS mean difference, 17.13; p=0.0185).
Conclusion In high ASCVD risk patients with T2DM, the combination of moderate-intensity rosuvastatin and ezetimibe was not only non-inferior but also superior to improving dyslipidemia with additional benefits compared to high-intensity rosuvastatin monotherapy.
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae Jin Kim, Hyun Min Kim, Jung Hae Ko, Nam Hoon Kim, Chong Hwa Kim, Jeeyun Ahn, Tae Jung Oh, Soo-Kyung Kim, Jaehyun Kim, Eugene Han, Sang-Man Jin, Won Suk Choi, Min Kyong Moon, Committee of Clinical Practice Guidelines, Korean Diabetes Association
Diabetes Metab J. 2023;47(5):575-594. Published online September 26, 2023
In May 2023, the Committee of Clinical Practice Guidelines of the Korean Diabetes Association published the revised clinical practice guidelines for Korean adults with diabetes and prediabetes. We incorporated the latest clinical research findings through a comprehensive systematic literature review and applied them in a manner suitable for the Korean population. These guidelines are designed for all healthcare providers nationwide, including physicians, diabetes experts, and certified diabetes educators who manage patients with diabetes or individuals at risk of developing diabetes. Based on recent changes in international guidelines and the results of a Korean epidemiological study, the recommended age for diabetes screening has been lowered. In collaboration with the relevant Korean medical societies, recently revised guidelines for managing hypertension and dyslipidemia in patients with diabetes have been incorporated into this guideline. An abridgment containing practical information on patient education and systematic management in the clinic was published separately.
Citations
Citations to this article as recorded by
Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim Metabolism.2024; 152: 155789. CrossRef
Letter by In-Kyung Jeong Regarding Article, Trends in Prevalence of Hypertriglyceridemia and Related Factors in Korean Adults: A Serial Cross-Sectional Study In-Kyung Jeong Journal of Lipid and Atherosclerosis.2024; 13(1): 80. CrossRef
Association between cardiovascular disease risk and incident type 2 diabetes mellitus in individuals with prediabetes: A retrospective cohort study Myung Jin Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee Diabetes Research and Clinical Practice.2024; 208: 111125. CrossRef
Korea Hypertension Fact Sheet 2023: analysis of nationwide population-based data with a particular focus on hypertension in special populations Hyeon Chang Kim, Hokyou Lee, Hyeok-Hee Lee, Dasom Son, Minsung Cho, Sojung Shin, Yeeun Seo, Eun-Jin kim, Song Vogue Ahn, Sun Ha Jee, Sungha Park, Hae-Young Lee, Min Ho Shin, Sang-Hyun Ihm, Seung Won Lee, Jong Ku Park, Il Suh, Tae-Yong Lee Clinical Hypertension.2024;[Epub] CrossRef
Diabetes Duration, Cholesterol Levels, and Risk of Cardiovascular Diseases in Individuals With Type 2 Diabetes Mee Kyoung Kim, Kyu Na Lee, Kyungdo Han, Seung-Hwan Lee The Journal of Clinical Endocrinology & Metabolism.2024;[Epub] CrossRef
Effect of Adding Apolipoprotein B Testing on the Prevalence of Dyslipidemia and Risk of Cardiovascular Disease in the Korean Adult Population Rihwa Choi, Sang Gon Lee, Eun Hee Lee Metabolites.2024; 14(3): 169. CrossRef
A self-powered and supercapacitive microneedle continuous glucose monitoring system with a wide range of glucose detection capabilities Hye-Jun Kil, Jang Hyeon Kim, Kanghae Lee, Tae-Uk Kang, Ju-Hyun Yoo, Yong-ho Lee, Jin-Woo Park Biosensors and Bioelectronics.2024; 257: 116297. CrossRef
Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history Jin Hwa Kim, Young Sang Lyu, BongSeong Kim, Mee Kyung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef
Management of Dyslipidemia in Patients with Diabetes Mellitus Kyung Ae Lee The Journal of Korean Diabetes.2023; 24(3): 111. CrossRef
2023 Clinical Practice Guidelines for Diabetes: Recommendations for Pharmacological Treatment of Type 2 Diabetes Junghyun Noh The Journal of Korean Diabetes.2023; 24(3): 127. CrossRef
2023 Clinical Practice Guidelines for Diabetes Min Kyong Moon The Journal of Korean Diabetes.2023; 24(3): 120. CrossRef
2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors Ye Seul Yang The Journal of Korean Diabetes.2023; 24(3): 135. CrossRef
A 33-Year-Old Man Presented with Abdominal Pain and Vomiting Starting a Day Ago Jong Han Choi The Korean Journal of Medicine.2023; 98(6): 289. CrossRef
Comorbidity Patterns and Management in Inpatients with Endocrine Diseases by Age Groups in South Korea: Nationwide Data Sung-Soo Kim, Hun-Sung Kim Journal of Personalized Medicine.2023; 14(1): 42. CrossRef
Da Young Lee, Namho Kim, Inha Jung, So Young Park, Ji Hee Yu, Ji A Seo, Jihee Kim, Kyeong Jin Kim, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Sung-Min Park, Nan Hee Kim
Diabetes Metab J. 2023;47(6):826-836. Published online August 24, 2023
Background There was limited evidence to evaluate the association between lifestyle habits and continuous glucose monitoring (CGM) metrics. Thus, we aimed to depict the behavioral and metabolic determinants of CGM metrics in insulin-treated patients with type 2 diabetes mellitus (T2DM).
Methods This is a prospective observational study. We analyzed data from 122 insulin-treated patients with T2DM. Participants wore Dexcom G6 and Fitbit, and diet information was identified for 10 days. Multivariate-adjusted logistic regression analysis was performed for the simultaneous achievement of CGM-based targets, defined by the percentage of time in terms of hyper, hypoglycemia and glycemic variability (GV). Intake of macronutrients and fiber, step counts, sleep, postprandial C-peptide-to-glucose ratio (PCGR), information about glucose lowering medications and metabolic factors were added to the analyses. Additionally, we evaluated the impact of the distribution of energy and macronutrient during a day, and snack consumption on CGM metrics.
Results Logistic regression analysis revealed that female, participants with high PCGR, low glycosylated hemoglobin (HbA1c) and daytime step count had a higher probability of achieving all targets based on CGM (odds ratios [95% confidence intervals] which were 0.24 [0.09 to 0.65], 1.34 [1.03 to 1.25], 0.95 [0.9 to 0.99], and 1.15 [1.03 to 1.29], respectively). And participants who ate snacks showed a shorter period of hyperglycemia and less GV compared to those without.
Conclusion We confirmed that residual insulin secretion, daytime step count, HbA1c, and women were the most relevant determinants of adequate glycemic control in insulin-treated patients with T2DM. In addition, individuals with snack consumption were exposed to lower times of hyperglycemia and GV.
Citations
Citations to this article as recorded by
Explanatory variables of objectively measured 24-h movement behaviors in people with prediabetes and type 2 diabetes: A systematic review Lotte Bogaert, Iris Willems, Patrick Calders, Eveline Dirinck, Manon Kinaupenne, Marga Decraene, Bruno Lapauw, Boyd Strumane, Margot Van Daele, Vera Verbestel, Marieke De Craemer Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(4): 102995. CrossRef
Background A substantial cardiovascular disease risk remains even after optimal statin therapy. Comparative predictiveness of major lipid and lipoprotein parameters for cardiovascular events in patients with type 2 diabetes mellitus (T2DM) who are treated with statins is not well documented.
Methods From the Korean Nationwide Cohort, 11,900 patients with T2DM (≥40 years of age) without a history of cardiovascular disease and receiving moderate- or high-intensity statins were included. The primary outcome was the first occurrence of major adverse cardiovascular events (MACE) including ischemic heart disease, ischemic stroke, and cardiovascular death. The risk of MACE was estimated according to on-statin levels of low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), highdensity lipoprotein cholesterol (HDL-C), and non-HDL-C.
Results MACE occurred in 712 patients during a median follow-up period of 37.9 months (interquartile range, 21.7 to 54.9). Among patients achieving LDL-C levels less than 100 mg/dL, the hazard ratios for MACE per 1-standard deviation change in ontreatment values were 1.25 (95% confidence interval [CI], 1.07 to 1.47) for LDL-C, 1.31 (95% CI, 1.09 to 1.57) for non-HDL-C, 1.05 (95% CI, 0.91 to 1.21) for TG, and 1.16 (95% CI, 0.98 to 1.37) for HDL-C, after adjusting for potential confounders and lipid parameters mutually. The predictive ability of on-statin LDL-C and non-HDL-C for MACE was prominent in patients at high cardiovascular risk or those with LDL-C ≥70 mg/dL.
Conclusion On-statin LDL-C and non-HDL-C levels are better predictors of the first cardiovascular event than TG or HDL-C in patients with T2DM.
Diabetic kidney disease (DKD) is a prevalent renal complication of diabetes mellitus that ultimately develops into end-stage kidney disease (ESKD) when not managed appropriately. Substantial risk of ESKD remains even with intensive management of hyperglycemia and risk factors of DKD and timely use of renin-angiotensin-aldosterone inhibitors. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce hyperglycemia primarily by inhibiting glucose and sodium reabsorption in the renal proximal tubule. Currently, their effects expand to prevent or delay cardiovascular and renal adverse events, even in those without diabetes. In dedicated renal outcome trials, SGLT2 inhibitors significantly reduced the risk of composite renal adverse events, including the development of ESKD or renal replacement therapy, which led to the positioning of SGLT2 inhibitors as the mainstay of chronic kidney disease management. Multiple mechanisms of action of SGLT2 inhibitors, including hemodynamic, metabolic, and anti-inflammatory effects, have been proposed. Restoration of tubuloglomerular feedback is a plausible explanation for the alteration in renal hemodynamics induced by SGLT2 inhibition and for the associated renal benefit. This review discusses the clinical rationale and mechanism related to the protection SGLT2 inhibitors exert on the kidney, focusing on renal hemodynamic effects.
Citations
Citations to this article as recorded by
Using intravoxel incoherent motion imaging to evaluate uric acid-induced renal injury and efficacy after treatment Zhong-Yuan Cheng, Shang-Ao Gong, Ping-Kang Chen, Zong-Chao Yu, Chen Qiu, Ji-Xin Lin, Jia-Bin Mo, Long Qian, You-Zhen Feng, Xiang-Ran Cai British Journal of Radiology.2024; 97(1153): 274. CrossRef
Rethinking eGFR Comparisons in SGLT2 Inhibitor Research Yuzuru Ohshiro Journal of the American College of Cardiology.2024; 83(9): e87. CrossRef
SGLT2 Inhibitors and Diabetes: Where Does It Come from and Where Does It Go? Ji Yoon Kim, Sin Gon Kim The Journal of Korean Diabetes.2024; 25(1): 9. CrossRef
Cardiorenal outcomes and mortality after sodium‐glucose cotransporter‐2 inhibitor initiation in type 2 diabetes patients with percutaneous coronary intervention history Jin Hwa Kim, Young Sang Lyu, BongSeong Kim, Mee Kyung Kim, Sang Yong Kim, Ki‐Hyun Baek, Ki‐Ho Song, Kyungdo Han, Hyuk‐Sang Kwon Diabetes, Obesity and Metabolism.2024;[Epub] CrossRef
Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis Yunke Ma, Chu Lin, Xiaoling Cai, Suiyuan Hu, Xingyun Zhu, Fang Lv, Wenjia Yang, Linong Ji Acta Diabetologica.2023; 60(3): 435. CrossRef
Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials Mengnan Li, Jian Zhang, Guimei Yang, Jiaxin Zhang, Minmin Han, Yi Zhang, Yunfeng Liu European Journal of Clinical Pharmacology.2023; 79(6): 859. CrossRef
Age at Mortality in Patients with Type 2 Diabetes Who Underwent Kidney Transplantation: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018 Sun Ok Song, Eugene Han, Kang Ju Son, Bong-Soo Cha, Byung-Wan Lee Journal of Clinical Medicine.2023; 12(9): 3160. CrossRef
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes Sjoukje van der Hoek, Jeroen V. Koomen, Erik J. M. van Bommel, Charlotte M. Mosterd, Rosalie A. Scholtes, Anne C. Hesp, Jasper Stevens, Daniel H. van Raalte, Hiddo J. L. Heerspink Journal of Personalized Medicine.2023; 13(5): 747. CrossRef
Osteopontin as a Biomarker in Chronic Kidney Disease Satyesh K. Sinha, Michael Mellody, Maria Beatriz Carpio, Robert Damoiseaux, Susanne B. Nicholas Biomedicines.2023; 11(5): 1356. CrossRef
Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee Metabolism.2023; 145: 155612. CrossRef
Synthesis and biological profile of benzoxazolone derivatives Parteek Prasher, Tanisqa Mall, Mousmee Sharma Archiv der Pharmazie.2023;[Epub] CrossRef
SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression Ye Jin Kim, Jonghwa Jin, Dong-Ho Kim, Daehoon Kim, You Mie Lee, Jun-Kyu Byun, Yeon-Kyung Choi, Keun-Gyu Park Inflammation Research.2023; 72(10-11): 1981. CrossRef
Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won
Diabetes Metab J. 2023;47(1):82-91. Published online June 20, 2022
Background To evaluate the safety and effectiveness of empagliflozin in routine clinical settings, we collected and assessed the clinical profiles of Korean patients with type 2 diabetes mellitus.
Methods This was a post-marketing surveillance study of empagliflozin 10 and 25 mg. Information on adverse events and adverse drug reactions (ADRs) was collected as safety data sets. Available effectiveness outcomes, including glycosylated hemoglobin (HbA1c) level, fasting plasma glucose, body weight, and blood pressure, were assessed.
Results The incidence rate of ADRs was 5.14% in the safety dataset (n=3,231). Pollakiuria, pruritis genital, and weight loss were the most common ADRs. ADRs of special interest accounted for only 1.18%, and there were no serious events that led to mortality or hospitalization. In the effectiveness data set (n=2,567), empagliflozin significantly reduced the mean HbA1c level and body weight during the study period by –0.68%±1.39% and –1.91±3.37 kg (both P<0.0001), respectively. In addition, shorter disease duration, absence of dyslipidemia, and higher baseline HbA1c levels were identified as the clinical features characteristic of a “responder” to empagliflozin therapy.
Conclusion Empagliflozin is a safe and potent glucose-lowering drug in routine use among Korean patients with type 2 diabetes mellitus. It is expected to have better glycemic efficacy in Korean patients with poorly controlled type 2 diabetes mellitus.
Citations
Citations to this article as recorded by
Evaluation of Efficacy and Safety of Empagliflozin in Bangladeshi Patients with Type 2 Diabetes Mellitus (EFFISAEM Study) Mohammad Saifuddin, Ajit Kumar Paul, Sultana Marufa Shefin, Md. Jahangir Alam, Shahjada Selim, Sunjida Islam, Tanjina Hossain, Sadiqa Tuqan, Nusrat Sultana, Marufa Mustari, Ramen Chandra Basak, Kazi Ali Aftab, Indrajit Prasad, Mohammad Rafiq Uddin, Shoma Indian Journal of Endocrinology and Metabolism.2024;[Epub] CrossRef
Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects Xu Jiang, Sungyeun Bae, Deok Yong Yoon, Shin Jung Park, Jaeseong Oh, Joo-Youn Cho, Kyung-Sang Yu Drug Design, Development and Therapy.2023; Volume 17: 2137. CrossRef
Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials Chun Xing Li, Li Yan Liu, Chen Xiao Zhang, Xu Hua Geng, Si Meng Gu, Yu Qiao Wang, Hua Liu, Qing Xie, Shuo Liang Frontiers in Endocrinology.2023;[Epub] CrossRef
Da Young Lee, Jaeyoung Kim, Sanghyun Park, So Young Park, Ji Hee Yu, Ji A Seo, Nam Hoon Kim, Hye Jin Yoo, Sin Gon Kim, Kyung Mook Choi, Sei Hyun Baik, Kyungdo Han, Nan Hee Kim
Diabetes Metab J. 2022;46(6):923-935. Published online May 24, 2022
Background We investigated whether fasting glucose (FG) variability could predict the risk of dementia.
Methods This cohort study analyzed data from Koreans with diabetes after at least three health examinations by the Korean National Health Insurance Corporation between 2005 and 2010, which included at least one examination between 2009 and 2010. A total of 769,554 individuals were included, excluding those aged <40 years and those with dementia. FG variability was measured using the variability independent of the mean (FG-VIM). The incidence of dementia was defined by the International Classification of Diseases 10th Revision codes and prescription of anti-dementia medication and was subdivided into Alzheimer’s disease (AD) and vascular dementia (VD).
Results During the 6.9-year follow-up, 54,837, 41,032, and 6,892 cases of all-cause dementia, AD, and VD, respectively, were identified. Cox proportional regression analyses showed that as the FG-VIM quartile increased, the risk of dementia serially increased after adjustment for metabolic factors, income status, and diabetes-related characteristics, including the mean FG. Participants in FG-VIM quartile 4 showed a 18%, 19%, and 17% higher risk for all-cause dementia, AD, and VD, respectively, than those in quartile 1; this particularly included non-obese patients with a longer duration of diabetes, high FG levels, dyslipidemia, and those taking glucose-lowering medications. Conversely, the baseline FG status and dementia showed a U-shaped association.
Conclusion Increased FG variability over 5 years can predict the risk of dementia in individuals with diabetes in Korea. This finding was more pronounced in patients with less favorable metabolic profiles.
Citations
Citations to this article as recorded by
Fasting glucose variability and risk of dementia in Parkinson’s disease: a 9-year longitudinal follow-up study of a nationwide cohort Sung Hoon Kang, Yunjin Choi, Su Jin Chung, Seok-Joo Moon, Chi Kyung Kim, Ji Hyun Kim, Kyungmi Oh, Joon Shik Yoon, Sang Won Seo, Geum Joon Cho, Seong-Beom Koh Frontiers in Aging Neuroscience.2024;[Epub] CrossRef
Effects of a Diabetic Microenvironment on Neurodegeneration: Special Focus on Neurological Cells Vishal Chavda, Dhananjay Yadav, Snehal Patel, Minseok Song Brain Sciences.2024; 14(3): 284. CrossRef
The Association of Glucose Variability and Dementia Incidence in Latinx Adults with Type 2 Diabetes: A Retrospective Study Heather Cuevas, Elizabeth Muñoz, Divya Nagireddy, Jeeyeon Kim, Grace Ganucheau, Fathia Alomoush Clinical Nursing Research.2023; 32(2): 249. CrossRef
The effects of long-term cumulative HbA1c exposure on the development and onset time of dementia in the patients with type 2 diabetes mellitus: Hospital based retrospective study (2005–2021) Sunyoung Cho, Choon Ok Kim, Bong-soo Cha, Eosu Kim, Chung Mo Nam, Min-Gul Kim, Min Soo Park Diabetes Research and Clinical Practice.2023; 201: 110721. CrossRef
Physiological Mechanisms Inherent to Diabetes Involved in the Development of Dementia: Alzheimer’s Disease Himan Mohamed-Mohamed, Victoria García-Morales, Encarnación María Sánchez Lara, Anabel González-Acedo, Teresa Pardo-Moreno, María Isabel Tovar-Gálvez, Lucía Melguizo-Rodríguez, Juan José Ramos-Rodríguez Neurology International.2023; 15(4): 1253. CrossRef
Cumulative effect of impaired fasting glucose on the risk of dementia in middle-aged and elderly people: a nationwide cohort study Jin Yu, Kyu-Na Lee, Hun-Sung Kim, Kyungdo Han, Seung-Hwan Lee Scientific Reports.2023;[Epub] CrossRef
Background The weight-adjusted waist index (WWI) reflected body compositional changes with aging. This study was to investigate the association of WWI with abdominal fat and muscle mass in a diverse race/ethnic population.
Methods Computed tomography (CT) data from 1,946 participants for abdominal fat and muscle areas from the Multi-Ethnic Study of Atherosclerosis (785 Whites, 252 Asians, 406 African American, and 503 Hispanics) were used. Among them, 595 participants underwent repeated CT. The WWI was calculated as waist circumference (cm) divided by the square root of body weight (kg). The associations of WWI with abdominal fat and muscle measures were examined, and longitudinal changes in abdominal composition measures were compared.
Results In all race/ethnic groups, WWI was positively correlated with total abdominal fat area (TFA), subcutaneous fat area, and visceral fat area, but negatively correlated with total abdominal muscle area (TMA) and abdominal muscle radiodensity (P<0.001 for all). WWI showed a linear increase with aging regardless of race and there were no significant differences in the WWI distribution between Whites, Asians, and African Americans. In longitudinal analyses, over 38.6 months of follow-up, all abdominal fat measures increased but muscle measures decreased, along with increase in WWI. The more the WWI increased, the more the TFA increased and the more the TMA decreased.
Conclusion WWI showed positive associations with abdominal fat mass and negative associations with abdominal muscle mass, which likely reflects the abdominal compositional changes with aging in a multi-ethnic population.
Citations
Citations to this article as recorded by
The association between weight-adjusted-waist index and depression: Results from NHANES 2005–2018 Meng Li, Xue Yu, Wenhui Zhang, Jiahui Yin, Lu Zhang, Guoshuai Luo, Yuanxiang Liu, Jiguo Yang Journal of Affective Disorders.2024; 347: 299. CrossRef
Association between weight-adjusted-waist index and gallstones: an analysis of the National Health and Nutrition Examination Survey Si-Hua Wen, Xin Tang, Tao Tang, Zheng-Rong Ye BMC Gastroenterology.2024;[Epub] CrossRef
Association between weight-adjusted waist index and myopia in adolescents and young adults: results from NHANES 1999–2008 Xu Han Shi, Li Dong, Rui Heng Zhang, Wen Bin Wei BMC Ophthalmology.2024;[Epub] CrossRef
Association between the weight-adjusted waist index and the odds of type 2 diabetes mellitus in United States adults: a cross-sectional study Dongdong Zheng, Suzhen Zhao, Dan Luo, Feng Lu, Zhishen Ruan, Xiaokang Dong, Wenjing Chen Frontiers in Endocrinology.2024;[Epub] CrossRef
Association between Weight-Adjusted Waist Index and depressive symptoms: A nationally representative cross-sectional study from NHANES 2005 to 2018 Hangyu Liu, Jin Zhi, Chuzhao Zhang, Shiyi Huang, Yang Ma, Dandan Luo, Lungang Shi Journal of Affective Disorders.2024; 350: 49. CrossRef
Relationship between cognitive function and weight-adjusted waist index in people ≥ 60 years old in NHANES 2011–2014 Xue-li Wang, Hong-lin Feng, Xiao-zhuo Xu, Jing Liu, Xu Han Aging Clinical and Experimental Research.2024;[Epub] CrossRef
Association between weight-adjusted waist index and non-alcoholic fatty liver disease: a population-based study Changhui Yu, Shiming He, Maobin Kuang, Chao Wang, Xin Huang, Guotai Sheng, Yang Zou BMC Endocrine Disorders.2024;[Epub] CrossRef
Association between weight-adjusted waist index and serum total testosterone in males aged 6–19 years in the United States: Data from NHANES 2013–2016 Zhifei Wu, Lingling Bao, Haiyan Wang, Jiajing Zheng, Yu Chen, Wenjuan Wang, Dongkai Qiu Heliyon.2024; 10(6): e27520. CrossRef
Associations of weight-adjusted-waist index and depression with secondary infertility Fei Sun, Min Liu, Shanshan Hu, Ruijie Xie, Huijuan Chen, Zhaona Sun, Huiya Bi Frontiers in Endocrinology.2024;[Epub] CrossRef
Association between weight-adjusted-waist index and depression in US adults: A cross-sectional study Yun Shen, Yahui Wu, Panru Luo, Minghan Fu, Kai Zhu, Jinsheng Wang Journal of Affective Disorders.2024; 355: 299. CrossRef
Age differences in the association of body mass index-defined obesity with abdominal aortic calcification Tangmeng Guo, Lili Huang, Zhijian Luo, Huabo Zheng, Shengshuai Shan, Bei Cheng Frontiers in Endocrinology.2024;[Epub] CrossRef
The relationship between weight-adjusted-waist index and diabetic kidney disease in patients with type 2 diabetes mellitus Zhaoxiang Wang, Xuejing Shao, Wei Xu, Bingshuang Xue, Shao Zhong, Qichao Yang Frontiers in Endocrinology.2024;[Epub] CrossRef
Assessment of existing anthropometric indices for screening sarcopenic obesity in older adults Jin Eui Kim, Jimi Choi, Miji Kim, Chang Won Won British Journal of Nutrition.2023; 129(5): 875. CrossRef
Relationship Between Weight-Adjusted Waist Index and Osteoporosis in the Senile in the United States from the National Health and Nutrition Examination Survey, 2017-2020 Yuxiang Lin, Zijie Liang, Anxin Zhang, Nuo Xu, Xuewen Pei, Nanbu Wang, Liang Zheng, Danghan Xu Journal of Clinical Densitometry.2023; 26(2): 101361. CrossRef
The association of asthma duration with body mass index and Weight-Adjusted-Waist index in a nationwide study of the U.S. adults Xiaoxiao Han, Xiaofang He, Gui Hao, Lifang Cao, Yinliang Qi, Kexing Han European Journal of Medical Research.2023;[Epub] CrossRef
Relationship between weight-adjusted-waist index and erectile dysfunction in the United State: results from NHANES 2001-2004 Shangqi Cao, Xu Hu, Yanxiang Shao, Yaohui Wang, Yaxiong Tang, Shangqing Ren, Xiang Li Frontiers in Endocrinology.2023;[Epub] CrossRef
The association between weight-adjusted-waist index and total bone mineral density in adolescents: NHANES 2011–2018 Xiaohua Wang, Shuo Yang, Gansheng He, Lin Xie Frontiers in Endocrinology.2023;[Epub] CrossRef
Asthma prevalence is increased in patients with high metabolism scores for visceral fat: study reports from the US Qiushi Liu, Xiaoxiao Han, Yan Chen, Ying Gao, Wei Yang, Lewei Huang Frontiers in Endocrinology.2023;[Epub] CrossRef
Positive association between weight-adjusted-waist index and dementia in the Chinese population with hypertension: a cross-sectional study Wei Zhou, Yanyou Xie, Lingling Yu, Chao Yu, Huihui Bao, Xiaoshu Cheng BMC Psychiatry.2023;[Epub] CrossRef
Associations between weight-adjusted waist index and bone mineral density: results of a nationwide survey Ya Zhang, Haiyang Wu, Cheng Li, Changxiong Liu, Mingjiang Liu, Xiaozhu Liu, Qiming Yin, Xianzhe Li, Ruijie Xie BMC Endocrine Disorders.2023;[Epub] CrossRef
Association of weight-adjusted-waist index with non-alcoholic fatty liver disease and liver fibrosis: a cross-sectional study based on NHANES Qinggang Hu, Kexing Han, Jiapei Shen, Weijie Sun, Long Gao, Yufeng Gao European Journal of Medical Research.2023;[Epub] CrossRef
Weight‐adjusted waist as an integrated index for fat, muscle and bone health in adults Kyoung Jin Kim, Serhim Son, Kyeong Jin Kim, Sin Gon Kim, Nam Hoon Kim Journal of Cachexia, Sarcopenia and Muscle.2023; 14(5): 2196. CrossRef
Association between weight-adjusted-waist index and female infertility: a population-based study Zujun Wen, Xiang Li Frontiers in Endocrinology.2023;[Epub] CrossRef
Association between weight-adjusted-waist index and risk of cardiovascular diseases in United States adults: a cross-sectional study Haiyang Fang, Feng Xie, Kai Li, Meng Li, Yanqing Wu BMC Cardiovascular Disorders.2023;[Epub] CrossRef
Association between the weight-adjusted waist index and stroke: a cross-sectional study Jiayi Ye, Yanjie Hu, Xinrong Chen, Zhe Yin, Xingzhu Yuan, Liping Huang, Ka Li BMC Public Health.2023;[Epub] CrossRef
Association between weight-adjusted-waist index and chronic kidney disease: a cross-sectional study Xiaowan Li, Lanyu Wang, Hongyi Zhou, Hongyang Xu BMC Nephrology.2023;[Epub] CrossRef
Sex Differences in the Association of Weight-Adjusted-Waist Index with Sarcopenic Obesity: A Cross-Sectional Study of Hemodialysis Patients Maolu Tian, Qin Lan, Fangfang Yu, Pinghong He, Shanshan Hu, Yan Zha Metabolic Syndrome and Related Disorders.2023; 21(10): 596. CrossRef
Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean? Eugene Han, Yong-ho Lee Clinical and Molecular Hepatology.2023; 29(4): 980. CrossRef
The association of body mass index and weight waist adjustment index with serum ferritin in a national study of US adults Hao Han, Ping Ni, Siqi Zhang, Xiaojuan Ji, Mingli Zhu, Wanyu Ma, Hongfeng Ge, Hailiang Chu European Journal of Medical Research.2023;[Epub] CrossRef
The weight-adjusted-waist index and cognitive impairment among U.S. older adults: a population-based study Xiao-tong Huang, Xiang Lv, Hong Jiang Frontiers in Endocrinology.2023;[Epub] CrossRef
The relationship between weight-adjusted-waist index and total bone mineral density in adults aged 20-59 Meiqian Guo, Yi Lei, Xueqing Liu, Xiang Li, Yong Xu, Donghui Zheng Frontiers in Endocrinology.2023;[Epub] CrossRef
Associations between weight-adjusted-waist index and infertility: Results from NHANES 2013 to 2020 Huanxin Zhong, Bin Yu, Fen Zhao, Hongyin Cui, Lifang You, Dao Feng, Yi Lu Medicine.2023; 102(48): e36388. CrossRef
The association between weight-adjusted-waist index and increased urinary albumin excretion in adults: A population-based study Zheng Qin, Kaixi Chang, Qinbo Yang, Qiao Yu, Ruoxi Liao, Baihai Su Frontiers in Nutrition.2022;[Epub] CrossRef
Association between the weight-adjusted-waist index and abdominal aortic calcification in United States adults: Results from the national health and nutrition examination survey 2013–2014 Feng Xie, Yuan Xiao, Xiaozhong Li, Yanqing Wu Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
The association between weight-adjusted-waist index and abdominal aortic calcification in adults aged ≥ 40 years: results from NHANES 2013–2014 Zheng Qin, Dongru Du, Yupei Li, Kaixi Chang, Qinbo Yang, Zhuyun Zhang, Ruoxi Liao, Baihai Su Scientific Reports.2022;[Epub] CrossRef
Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo-Kyung Kim, Seung-Hwan Lee, Jae-Seung Yun, Jong Ha Baek, Junghyun Noh, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Ye Seul Yang, Jang Won Son, Jong Han Choi, Kee Ho Song, Nam Hoon Kim, Sang Yong Kim, Jin Wha Kim, Sang Youl Rhee, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim, Chong Hwa Kim, Dae Jung Kim, SungWan Chun, Eun-Jung Rhee, Hyun Min Kim, Hyun Jung Kim, Donghyun Jee, Jae Hyun Kim, Won Seok Choi, Eun-Young Lee, Kun-Ho Yoon, Seung-Hyun Ko, Committee of Clinical Practice Guidelines, Korean Diabetes Association
Diabetes Metab J. 2021;45(4):461-481. Published online July 30, 2021
The Committee of Clinical Practice Guidelines of the Korean Diabetes Association (KDA) updated the previous clinical practice guidelines for Korean adults with diabetes and prediabetes and published the seventh edition in May 2021. We performed a comprehensive systematic review of recent clinical trials and evidence that could be applicable in real-world practice and suitable for the Korean population. The guideline is provided for all healthcare providers including physicians, diabetes experts, and certified diabetes educators across the country who manage patients with diabetes or the individuals at the risk of developing diabetes mellitus. The recommendations for screening diabetes and glucose-lowering agents have been revised and updated. New sections for continuous glucose monitoring, insulin pump use, and non-alcoholic fatty liver disease in patients with diabetes mellitus have been added. The KDA recommends active vaccination for coronavirus disease 2019 in patients with diabetes during the pandemic. An abridgement that contains practical information for patient education and systematic management in the clinic was published separately.
Citations
Citations to this article as recorded by
Impact of Subclinical Atrial Function on the Prognosis of Patients With Atrial Fibrillation and Metabolic Syndrome Hyun-Jin Kim CardioMetabolic Syndrome Journal.2024; 4(1): 36. CrossRef
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study Nam Hoon Kim, Ji Yoon Kim, Jimi Choi, Sin Gon Kim European Heart Journal - Cardiovascular Pharmacotherapy.2024; 10(2): 118. CrossRef
A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inh Hae Jin Kim, Jung Hyun Noh, Min Kyong Moon, Sung Hee Choi, Seung-Hyun Ko, Eun-Jung Rhee, Kyu Yeon Hur, In-Kyung Jeong, Mark Yorek Journal of Diabetes Research.2024; 2024: 1. CrossRef
Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin as Metformin Add-on in a Korean Population with Type 2 Diabetes Byung-Wan Lee, Young Min Cho, Sin Gon Kim, Seung-Hyun Ko, Soo Lim, Amine Dahaoui, Jin Sook Jeong, Hyo Jin Lim, Jae Myung Yu Diabetes Therapy.2024; 15(2): 547. CrossRef
Real-World Continuous Glucose Monitoring Data from a Population with Type 1 Diabetes in South Korea: Nationwide Single-System Analysis Ji Yoon Kim, Sang-Man Jin, Sarah Andrade, Boyang Chen, Jae Hyeon Kim Diabetes Technology & Therapeutics.2024;[Epub] CrossRef
Association between Dyslipidemia and Glycated Hemoglobin in a Population-Based Study Purum Kang, Ka Young Kim, Hye Young Shin Metabolites.2024; 14(2): 92. CrossRef
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Soo Lim, Woojoo Lee, Won Kim JAMA Internal Medicine.2024; 184(4): 375. CrossRef
View on Metformin: Antidiabetic and Pleiotropic Effects, Pharmacokinetics, Side Effects, and Sex-Related Differences Guglielmina Froldi Pharmaceuticals.2024; 17(4): 478. CrossRef
Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial Ji Yoon Kim, Sang-Man Jin, Eun Seok Kang, Soo Heon Kwak, Yeoree Yang, Jee Hee Yoo, Jae Hyun Bae, Jun Sung Moon, Chang Hee Jung, Ji Cheol Bae, Sunghwan Suh, Sun Joon Moon, Sun Ok Song, Suk Chon, Jae Hyeon Kim Diabetologia.2024;[Epub] CrossRef
Efficacy of intermittent short‐term use of a real‐time continuous glucose monitoring system in non‐insulin–treated patients with type 2 diabetes: A randomized controlled trial Sun Joon Moon, Kyung‐Soo Kim, Woo Je Lee, Mi Yeon Lee, Robert Vigersky, Cheol‐Young Park Diabetes, Obesity and Metabolism.2023; 25(1): 110. CrossRef
Therapeutic Effects of Switching to Anagliptin from Other DPP-4 Inhibitors in T2DM Patients with Inadequate Glycemic Control: A Non-interventional, Single-Arm, Open-Label, Multicenter Observational Study Sang-Yong Kim, Sungrae Kim Diabetes Therapy.2023; 14(1): 109. CrossRef
Low Skeletal Muscle Mass Accompanied by Abdominal Obesity Additively Increases the Risk of Incident Type 2 Diabetes Ji Eun Jun, Seung-Eun Lee, You-Bin Lee, Gyuri Kim, Sang-Man Jin, Jae Hwan Jee, Jae Hyeon Kim The Journal of Clinical Endocrinology & Metabolism.2023; 108(5): 1173. CrossRef
Diabetes screening in South Korea: a new estimate of the number needed to screen to detect diabetes Kyoung Hwa Ha, Kyung Ae Lee, Kyung-Do Han, Min Kyong Moon, Dae Jung Kim The Korean Journal of Internal Medicine.2023; 38(1): 93. CrossRef
Justicia carnea extracts ameliorated hepatocellular damage in streptozotocin-induced type 1 diabetic male rats via decrease in oxidative stress, inflammation and increasing other risk markers John Adeolu Falode, Oluwaseun Igbekele Ajayi, Tolulope Victoria Isinkaye, Akinwunmi Oluwaseun Adeoye, Basiru Olaitan Ajiboye, Bartholomew I. C. Brai Biomarkers.2023; 28(2): 177. CrossRef
Sex differences in the impact of diabetes mellitus on tuberculosis recurrence: a retrospective national cohort study Dararat Eksombatchai, Dawoon Jeong, Jeongha Mok, Doosoo Jeon, Hee-Yeon Kang, Hee Jin Kim, Hee-Sun Kim, Hongjo Choi, Young Ae Kang International Journal of Infectious Diseases.2023; 127: 1. CrossRef
The Predictive Ability of C-Peptide in Distinguishing Type 1 Diabetes From Type 2 Diabetes: A Systematic Review and Meta-Analysis Sajid Iqbal, Abdulrahim Abu Jayyab, Ayah Mohammad Alrashdi, Silvia Reverté-Villarroya Endocrine Practice.2023; 29(5): 379. CrossRef
Anagliptin twice‐daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double‐blind, randomized controlled trial Yong‐ho Lee, Doo‐Man Kim, Jae Myung Yu, Kyung Mook Choi, Sin Gon Kim, Kang Seo Park, Hyun‐Shik Son, Choon Hee Chung, Kyu Jeung Ahn, Soon Hee Lee, Ki‐Ho Song, Su Kyoung Kwon, Hyeong Kyu Park, Kyu Chang Won, Hak Chul Jang Diabetes, Obesity and Metabolism.2023; 25(5): 1174. CrossRef
Implementation of five machine learning methods to predict the 52-week blood glucose level in patients with type 2 diabetes Xiaomin Fu, Yuhan Wang, Ryan S. Cates, Nan Li, Jing Liu, Dianshan Ke, Jinghua Liu, Hongzhou Liu, Shuangtong Yan Frontiers in Endocrinology.2023;[Epub] CrossRef
Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon Journal of Lipid and Atherosclerosis.2023; 12(1): 12. CrossRef
The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study Minyoung Kim, Hosu Kim, Kyong Young Kim, Soo Kyoung Kim, Junghwa Jung, Jong Ryeal Hahm, Jaehoon Jung, Jong Ha Baek Diabetes & Metabolism Journal.2023; 47(1): 135. CrossRef
Safety and Effectiveness of Empagliflozin in Korean Patients with Type 2 Diabetes Mellitus: Results from a Nationwide Post-Marketing Surveillance Jun Sung Moon, Nam Hoon Kim, Jin Oh Na, Jae Hyoung Cho, In-Kyung Jeong, Soon Hee Lee, Ji-Oh Mok, Nan Hee Kim, Dong Jin Chung, Jinhong Cho, Dong Woo Lee, Sun Woo Lee, Kyu Chang Won Diabetes & Metabolism Journal.2023; 47(1): 82. CrossRef
Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon International Journal of Heart Failure.2023; 5(1): 1. CrossRef
Influenza vaccination trend and related factors among patients with diabetes in Korea: Analysis using a nationwide database Dong-Hwa Lee, Bumhee Yang, Seonhye Gu, Eung-Gook Kim, Youlim Kim, Hyung Koo Kang, Yeong Hun Choe, Hyun Jeong Jeon, Seungyong Park, Hyun Lee Frontiers in Endocrinology.2023;[Epub] CrossRef
Optimal Low-Density Lipoprotein Cholesterol Level for Primary Prevention in Koreans with Type 2 Diabetes Mellitus Ji Yoon Kim, Nam Hoon Kim Diabetes & Metabolism Journal.2023; 47(1): 42. CrossRef
Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement Kyu-Sun Lee, Junghyun Noh, Seong-Mi Park, Kyung Mook Choi, Seok-Min Kang, Kyu-Chang Won, Hyun-Jai Cho, Min Kyong Moon Diabetes & Metabolism Journal.2023; 47(1): 10. CrossRef
Lipid Management in Korean People with Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon Diabetes & Metabolism Journal.2023; 47(1): 1. CrossRef
Association between Low-Density Lipoprotein Cholesterol Level and Cardiovascular Outcomes in Korean Adults: A Nationwide Cohort Study Junghyun Noh, Min Kyong Moon, Eun-Jung Rhee, Sang Hyun Park, Hyeon Chang Kim, Byung Jin Kim, Hae Jin Kim, Seonghoon Choi, Jin Oh Na, Young Youl Hyun, Bum Joon Kim, Kyung-Do Han, In-Kyung Jeong Diabetes & Metabolism Journal.2023; 47(1): 59. CrossRef
Analysis of the Incidence of Type 2 Diabetes, Requirement of Insulin Treatment, and Diabetes-Related Complications among Patients with Cancer Su Jung Lee, Chulho Kim, Hyunjae Yu, Dong-Kyu Kim Cancers.2023; 15(4): 1094. CrossRef
The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension Hack-Lyoung Kim, Eun Mi Lee, Shin Young Ahn, Kwang-il Kim, Hyeon Chang Kim, Ju Han Kim, Hae-Young Lee, Jang Hoon Lee, Jong-Moo Park, Eun Joo Cho, Sungha Park, Jinho Shin, Young-Kwon Kim Clinical Hypertension.2023;[Epub] CrossRef
Consistency of 1-day and 3-day average dietary intake and the relationship of dietary intake with blood glucose, hbA1c, BMI, and lipids in patients with type 2 diabetes DaeEun Lee, Haejung Lee, Sangeun Lee, MinJin Lee, Ah Reum Khang Journal of Korean Biological Nursing Science.2023; 25(1): 20. CrossRef
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study Kyung-Soo Kim, Kyung Ah Han, Tae Nyun Kim, Cheol-Young Park, Jung Hwan Park, Sang Yong Kim, Yong Hyun Kim, Kee Ho Song, Eun Seok Kang, Chul Sik Kim, Gwanpyo Koh, Jun Goo Kang, Mi Kyung Kim, Ji Min Han, Nan Hee Kim, Ji Oh Mok, Jae Hyuk Lee, Soo Lim, Sang S Diabetes & Metabolism.2023; 49(4): 101440. CrossRef
Effect of olmesartan and amlodipine on serum angiotensin-(1–7) levels and kidney and vascular function in patients with type 2 diabetes and hypertension Kyuho Kim, Ji Hye Moon, Chang Ho Ahn, Soo Lim Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
Menopausal hormone therapy and the risk of type 2 diabetes mellitus: Health Insurance Database in South Korea–based retrospective cohort study Jin-Sung Yuk, Jung Min Kim Menopause.2023; 30(5): 497. CrossRef
Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus Takayoshi Sasako, Toshimasa Yamauchi, Kohjiro Ueki Diabetes & Metabolism Journal.2023; 47(2): 185. CrossRef
Association between antidiabetic drugs and the incidence of atrial fibrillation in patients with type 2 diabetes: A nationwide cohort study in South Korea Sunyoung Kim, So Young Park, Bongseong Kim, Chanyang Min, Wonyoung Cho, Dong Keon Yon, Joo Young Kim, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee, Sang Youl Rhee Diabetes Research and Clinical Practice.2023; 198: 110626. CrossRef
Totally robotic Roux-en-Y gastric bypass in a morbidly obese patient in Korea: a case report Ji Won Seo, Kyong-Hwa Jun Journal of Minimally Invasive Surgery.2023; 26(1): 40. CrossRef
Effect of diabetes-specific oral nutritional supplements with allulose on weight and glycemic profiles in overweight or obese type 2 diabetic patients Jihye Tak, Minkyung Bok, Hyunkyung Rho, Ju Hyun Park, Yunsook Lim, Suk Chon, Hyunjung Lim Nutrition Research and Practice.2023; 17(2): 241. CrossRef
Associations Between Modifiable Risk Factors and Changes in Glycemic Status Among Individuals With Prediabetes Salma Nabila, Ji-Eun Kim, Jaesung Choi, JooYong Park, Aesun Shin, Sang-Ah Lee, Jong-koo Lee, Daehee Kang, Ji-Yeob Choi Diabetes Care.2023; 46(3): 535. CrossRef
Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial Soo Heon Kwak, Kyung Ah Han, Kyung‐Soo Kim, Jae Myung Yu, EunSook Kim, Jong Chul Won, Jun Goo Kang, Choon Hee Chung, Seungjoon Oh, Sung Hee Choi, Kyu Chang Won, Sin Gon Kim, Seung Ah Cho, Bo Young Cho, Kyong Soo Park Diabetes, Obesity and Metabolism.2023; 25(7): 1865. CrossRef
Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review Siew Pheng Chan, Lee-Ling Lim, Juliana C. N. Chan, David R. Matthews Diabetes Therapy.2023; 14(5): 823. CrossRef
The association of perfluoroalkyl substances (PFAS) exposure and kidney function in Korean adolescents using data from Korean National Environmental Health Survey (KoNEHS) cycle 4 (2018–2020): a cross-sectional study Jisuk Yun, Eun-Chul Jang, Soon-Chan Kwon, Young-Sun Min, Yong-Jin Lee Annals of Occupational and Environmental Medicine.2023;[Epub] CrossRef
A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects Hyun Chul Kim, Sangmi Lee, Siyoung Sung, Eunjin Kim, In-Jin Jang, Jae-Yong Chung Drug Design, Development and Therapy.2023; Volume 17: 1203. CrossRef
Efficacy and safety of monotherapy with enavogliflozin in Korean patients with type 2 diabetes mellitus: Results of a 12‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase 2 trial Ye Seul Yang, Kyung Wan Min, Seok‐O Park, Kyung‐Soo Kim, Jae Myung Yu, Eun‐Gyoung Hong, Sung Rae Cho, Kyu Chang Won, Yong Hyun Kim, Seungjoon Oh, Sung Hee Choi, Gwanpyo Koh, Wan Huh, Su Young Kim, Kyong Soo Park Diabetes, Obesity and Metabolism.2023; 25(8): 2096. CrossRef
An Integrated Digital Health Care Platform for Diabetes Management With AI-Based Dietary Management: 48-Week Results From a Randomized Controlled Trial You-Bin Lee, Gyuri Kim, Ji Eun Jun, Hyunjin Park, Woo Je Lee, You-Cheol Hwang, Jae Hyeon Kim Diabetes Care.2023; 46(5): 959. CrossRef
Performance of Simple Fibrosis Score in Non-Alcoholic Fatty Liver Disease with and without Type 2 Diabetes Seung Min Chung, Min Kyu Kang, Jun Sung Moon, Jung Gil Park Endocrinology and Metabolism.2023; 38(2): 277. CrossRef
Correlation analysis of cancer incidence after pravastatin treatment Jin Yu, Raeun Kim, Jiwon Shinn, Man Young Park, Hun-Sung Kim Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 61. CrossRef
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The gemi‐heart study Seung Min Chung, Jun Sung Moon, Jun Hwa Hong, In‐Chang Hwang, Soo Lim Diabetes, Obesity and Metabolism.2023; 25(8): 2181. CrossRef
The era of continuous glucose monitoring and its expanded role in type 2 diabetes Jin Yu, Jae‐Hyoung Cho, Seung‐Hwan Lee Journal of Diabetes Investigation.2023; 14(7): 841. CrossRef
Impact of continuous glucose monitoring on glycemic control and its derived metrics in type 1 diabetes: a longitudinal study So Hyun Cho, Seohyun Kim, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Gyuri Kim, Jae Hyeon Kim Frontiers in Endocrinology.2023;[Epub] CrossRef
Impact of mental disorders on the risk of heart failure among Korean patients with diabetes: a cohort study Tae Kyung Yoo, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee Cardiovascular Diabetology.2023;[Epub] CrossRef
Asia-Pacific consensus recommendations for application of continuous glucose monitoring in diabetes management Alice P.S. Kong, Soo Lim, Seung-Hyun Yoo, Linong Ji, Liming Chen, Yuqian Bao, Ester Yeoh, Siew-Pheng Chan, Chih-Yuan Wang, Viswanathan Mohan, Neale Cohen, Margaret J. McGill, Stephen M. Twigg Diabetes Research and Clinical Practice.2023; 201: 110718. CrossRef
Chronic disease management program applied to type 2 diabetes patients and prevention of diabetic complications: a retrospective cohort study using nationwide data Min Kyung Hyun, Jang Won Lee, Seung-Hyun Ko BMC Public Health.2023;[Epub] CrossRef
Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017 Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park Diabetes & Metabolism Journal.2023; 47(3): 347. CrossRef
Opening the Precision Diabetes Care through Digital Healthcare Joonyub Lee, Jin Yu, Kun-Ho Yoon Diabetes & Metabolism Journal.2023; 47(3): 307. CrossRef
Glycemia according to the Use of Continuous Glucose Monitoring among Adults with Type 1 Diabetes Mellitus in Korea: A Real-World Study You-Bin Lee, Minjee Kim, Jae Hyeon Kim Diabetes & Metabolism Journal.2023; 47(3): 405. CrossRef
Navigating the Seas of Glycemic Control: The Role of Continuous Glucose Monitoring in Type 1 Diabetes Mellitus Jun Sung Moon Diabetes & Metabolism Journal.2023; 47(3): 345. CrossRef
Lost in translation: assessing the nomenclature change for diabetic kidney disease in Japan Tetsuya Babazono, Tatsumi Moriya Diabetology International.2023; 14(4): 319. CrossRef
Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study Hyeong Kyu Park, Kyoung‐Ah Kim, Kyung‐Wan Min, Tae‐Seo Sohn, In Kyung Jeong, Chul Woo Ahn, Nan‐Hee Kim, Ie Byung Park, Ho Chan Cho, Choon Hee Chung, Sung Hee Choi, Kang Seo Park, Seoung‐Oh Yang, Kwan Woo Lee Diabetes, Obesity and Metabolism.2023; 25(9): 2743. CrossRef
Topic Modeling Analysis of Diabetes-Related Health Information during the Coronavirus Disease Pandemic Soyoon Min, Jeongwon Han Healthcare.2023; 11(13): 1871. CrossRef
Screening Test for Evaluation of Cardiovascular Disease in Patients with Diabetes Ji-Oh Mok, Chan-Hee Jung The Journal of Korean Diabetes.2023; 24(2): 76. CrossRef
Paradigm Shift in Management of Hyperglycemia in Patients with Type 2 Diabetes: Glucocentric versus Organ Protection Jong Chul Won The Journal of Korean Diabetes.2023; 24(2): 59. CrossRef
Association between type 2 diabetes mellitus and depression among Korean midlife women: a cross-sectional analysis study You Lee Yang, Eun-Ok Im, Yunmi Kim BMC Nursing.2023;[Epub] CrossRef
Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong Gut and Liver.2023; 17(4): 610. CrossRef
Association between the number of pregnancies and cardiac target organ damages: a cross-sectional analysis of data from the Korean women’s chest pain registry (KoROSE) Hack-Lyoung Kim, Hyun-Jin Kim, Mina Kim, Sang Min Park, Hyun Ju Yoon, Young Sup Byun, Seong-Mi Park, Mi-Seung Shin, Kyung-Soon Hong, Myung-A Kim BMC Women's Health.2023;[Epub] CrossRef
Exercise therapy for diabetes mellitus Chaiho Jeong, Tae-Seo Sohn Journal of the Korean Medical Association.2023; 66(7): 427. CrossRef
Medical nutrition therapy for diabetes mellitus Suk Chon Journal of the Korean Medical Association.2023; 66(7): 421. CrossRef
Identification of individuals at risk of hepatocellular carcinoma: screening for clinically significant liver fibrosis in patients with T2DM Tina Reinson, Ryan M Buchanan, Christopher D Byrne Expert Review of Endocrinology & Metabolism.2023; 18(5): 355. CrossRef
Additive impact of diabetes and sarcopenia on all-cause and cardiovascular mortality: A longitudinal nationwide population-based study Eyun Song, Soon Young Hwang, Min Jeong Park, Ahreum Jang, Kyeong Jin Kim, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A. Seo, Sin Gon Kim, Nan Hee Kim, Sei Hyun Baik, Kyung Mook Choi Metabolism.2023; 148: 155678. CrossRef
Exposure to perfluoroalkyl and polyfluoroalkyl substances and risk of stroke in adults: a meta-analysis Min Cheol Chang, Seung Min Chung, Sang Gyu Kwak Reviews on Environmental Health.2023;[Epub] CrossRef
Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis Mee Kyoung Kim, Kyungdo Han, Hyuk-Sang Kwon, Soon Jib Yoo Endocrinology and Metabolism.2023; 38(4): 426. CrossRef
Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients Sanghwa Park, Jiseon Jeong, Yunna Woo, Yeo Jin Choi, Sooyoung Shin Scientific Reports.2023;[Epub] CrossRef
Dyslipidemia Fact Sheet in South Korea, 2022 Eun-Sun Jin, Jee-Seon Shim, Sung Eun Kim, Jae Hyun Bae, Shinae Kang, Jong Chul Won, Min-Jeong Shin, Heung Yong Jin, Jenny Moon, Hokyou Lee, Hyeon Chang Kim, In-Kyung Jeong Journal of Lipid and Atherosclerosis.2023; 12(3): 237. CrossRef
Diabetes Mellitus in the Elderly Adults in Korea: Based on Data from the Korea National Health and Nutrition Examination Survey 2019 to 2020 Seung-Hyun Ko, Kyung Do Han, Yong-Moon Park, Jae-Seung Yun, Kyuho Kim, Jae-Hyun Bae, Hyuk-Sang Kwon, Nan-Hee Kim Diabetes & Metabolism Journal.2023; 47(5): 643. CrossRef
Management of Dyslipidemia in Patients with Diabetes Mellitus Kyung Ae Lee The Journal of Korean Diabetes.2023; 24(3): 111. CrossRef
2023 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Factors Ye Seul Yang The Journal of Korean Diabetes.2023; 24(3): 135. CrossRef
Dyslipidemia Fact Sheet in South Korea, 2022 Eun-Sun Jin, Jee-Seon Shim, Sung Eun Kim, Jae Hyun Bae, Shinae Kang, Jong Chul Won, Min-Jeong Shin, Heung Yong Jin, Jenny Moon, Hokyou Lee, Hyeon Chang Kim, In-Kyung Jeong Diabetes & Metabolism Journal.2023; 47(5): 632. CrossRef
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J Diabetes & Metabolism Journal.2023; 47(5): 575. CrossRef
Riesgo residual. Conclusiones Ángel Cequier, José Luis Zamorano Revista Española de Cardiología Suplementos.2023; 23: 25. CrossRef
Intake of Fruit and Glycemic Control in Korean Patients with Diabetes Mellitus Using the Korea National Health and Nutrition Examination Survey Eunju Yoon, Ji Cheol Bae, Sunghwan Suh Endocrinology and Metabolism.2023; 38(5): 538. CrossRef
2023 Clinical Practice Guidelines for Diabetes Min Kyong Moon The Journal of Korean Diabetes.2023; 24(3): 120. CrossRef
Cumulative effect of impaired fasting glucose on the risk of dementia in middle-aged and elderly people: a nationwide cohort study Jin Yu, Kyu-Na Lee, Hun-Sung Kim, Kyungdo Han, Seung-Hwan Lee Scientific Reports.2023;[Epub] CrossRef
Coleus forskohlii Root Extract (ForcslimTM) as a Prospective Antidiabetic Agent: In vitro Glucose Uptake Stimulation and α-Amylase Inhibitory Effects Firoz Hirehal Hussain Mi, Channangihalli Thimmegowda Sadashiva, Neethumol Benny, Sreedrisya Ayippakkari Kuttiattu, Ravi Subban International Journal of Pharmacology.2023; 19(5): 730. CrossRef
Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus Ji Yoon Kim, Jimi Choi, Sin Gon Kim, Nam Hoon Kim Diabetes & Metabolism Journal.2023; 47(6): 837. CrossRef
Differential Impact of Obesity on the Risk of Diabetes Development in Two Age Groups: Analysis from the National Health Screening Program Tae Kyung Yoo, Kyung-Do Han, Yang-Hyun Kim, Ga Eun Nam, Sang Hyun Park, Eun-Jung Rhee, Won-Young Lee Diabetes & Metabolism Journal.2023; 47(6): 846. CrossRef
Strategies to Maintain the Remission of Diabetes Following Metabolic Surgery Mi Kyung Kim, Hye Soon Kim Journal of Metabolic and Bariatric Surgery.2023; 12(2): 26. CrossRef
East Asian perspectives in metabolic and bariatric surgery Tae Jung Oh, Hyuk‐Joon Lee, Young Min Cho Journal of Diabetes Investigation.2022; 13(5): 756. CrossRef
Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus Jin Yu, Seung-Hwan Lee, Mee Kyoung Kim Endocrinology and Metabolism.2022; 37(1): 26. CrossRef
Association between Physical Exercise and Glycated Hemoglobin Levels in Korean Patients Diagnosed with Diabetes Il Yun, Hye Jin Joo, Yu Shin Park, Eun-Cheol Park International Journal of Environmental Research and Public Health.2022; 19(6): 3280. CrossRef
Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double‐blind, and placebo‐controlled study Minyoung Lee, Woo‐je Lee, Jae Hyeon Kim, Byung‐Wan Lee Diabetes, Obesity and Metabolism.2022; 24(6): 1105. CrossRef
Trends of severe hypoglycemia in patients with type 2 diabetes in Korea: A longitudinal nationwide cohort study Jae‐Seung Yun, Kyungdo Han, Seung‐Hyun Ko Journal of Diabetes Investigation.2022; 13(8): 1438. CrossRef
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim, Ji A Seo Kidney Research and Clinical Practice.2022; 41(2): 136. CrossRef
Cardiorenal Risk Profiles Among Data-Driven Type 2 Diabetes Sub-Phenotypes: A Post-Hoc Analysis of the China Health and Nutrition Survey Hui Gao, Kan Wang, Wensui Zhao, Jianlin Zhuang, Yu Jiang, Lei Zhang, Qingping Liu, Fariba Ahmadizar Frontiers in Endocrinology.2022;[Epub] CrossRef
Individualized Medical Nutrition Therapy for Diabetic Patients according to Diabetes Medication Juyeon Park The Journal of Korean Diabetes.2022; 23(1): 50. CrossRef
Critical shear stress of red blood cells as a novel integrated biomarker for screening chronic kidney diseases in cases of type 2 diabetes Il Rae Park, Jimi Choi, Eun Young Ha, Seung Min Chung, Jun Sung Moon, Sehyun Shin, Sin Gon Kim, Kyu Chang Won Clinical Hemorheology and Microcirculation.2022; 81(4): 293. CrossRef
Effects of exercise on reducing diabetes risk in Korean women according to menopausal status Jung-Hwan Cho, Hye-Mi Kwon, Se-Eun Park, Ju-Hwan Yoo, Kyung-Do Han, Eun-Jung Rhee, Won-Young Lee Cardiovascular Prevention and Pharmacotherapy.2022; 4(2): 75. CrossRef
Novel Glycemic Index Based on Continuous Glucose Monitoring to Predict Poor Clinical Outcomes in Critically Ill Patients: A Pilot Study Eun Yeong Ha, Seung Min Chung, Il Rae Park, Yin Young Lee, Eun Young Choi, Jun Sung Moon Frontiers in Endocrinology.2022;[Epub] CrossRef
Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison Han Na Jung, Yun Kyung Cho, Se Hee Min, Hwi Seung Kim, Ye-Jee Kim, Joong-Yeol Park, Woo Je Lee, Chang Hee Jung Frontiers in Endocrinology.2022;[Epub] CrossRef
Obesity, hypertension, diabetes mellitus, and hypercholesterolemia in Korean adults before and during the COVID-19 pandemic: a special report of the 2020 Korea National Health and Nutrition Examination Survey Ga Bin Lee, Yoonjung Kim, Suyeon Park, Hyeon Chang Kim, Kyungwon Oh Epidemiology and Health.2022; 44: e2022041. CrossRef
Adherence to healthy lifestyle behaviors as a preventable risk factor for severe hypoglycemia in people with type 2 diabetes: A longitudinal nationwide cohort study Jae‐Seung Yun, Kyungdo Han, Yong‐Moon Park, Eugene Han, Yong‐ho Lee, Seung‐Hyun Ko Journal of Diabetes Investigation.2022; 13(9): 1533. CrossRef
Diabetes Fact Sheet in Korea 2021 Jae Hyun Bae, Kyung-Do Han, Seung-Hyun Ko, Ye Seul Yang, Jong Han Choi, Kyung Mook Choi, Hyuk-Sang Kwon, Kyu Chang Won Diabetes & Metabolism Journal.2022; 46(3): 417. CrossRef
Comprehensive Understanding for Application in Korean Patients with Type 2 Diabetes Mellitus of the Consensus Statement on Carbohydrate-Restricted Diets by Korean Diabetes Association, Korean Society for the Study of Obesity, and Korean Society of Hyperte Jong Han Choi, Jee-Hyun Kang, Suk Chon Diabetes & Metabolism Journal.2022; 46(3): 377. CrossRef
Effect of Carbohydrate-Restricted Diets and Intermittent Fasting on Obesity, Type 2 Diabetes Mellitus, and Hypertension Management: Consensus Statement of the Korean Society for the Study of Obesity, Korean Diabetes Association, and Korean Society of Hype Jong Han Choi, Yoon Jeong Cho, Hyun-Jin Kim, Seung-Hyun Ko, Suk Chon, Jee-Hyun Kang, Kyoung-Kon Kim, Eun Mi Kim, Hyun Jung Kim, Kee-Ho Song, Ga Eun Nam, Kwang Il Kim Diabetes & Metabolism Journal.2022; 46(3): 355. CrossRef
Effect of carbohydrate-restricted diets and intermittent fasting on obesity, type 2 diabetes mellitus, and hypertension management: consensus statement of the Korean Society for the Study of obesity, Korean Diabetes Association, and Korean Society of Hype Jong Han Choi, Yoon Jeong Cho, Hyun-Jin Kim, Seung-Hyun Ko, Suk Chon, Jee-Hyun Kang, Kyoung-Kon Kim, Eun Mi Kim, Hyun Jung Kim, Kee-Ho Song, Ga Eun Nam, Kwang Il Kim Clinical Hypertension.2022;[Epub] CrossRef
Efficacy of Personalized Diabetes Self-care Using an Electronic Medical Record–Integrated Mobile App in Patients With Type 2 Diabetes: 6-Month Randomized Controlled Trial Eun Young Lee, Seon-Ah Cha, Jae-Seung Yun, Sun-Young Lim, Jin-Hee Lee, Yu-Bae Ahn, Kun-Ho Yoon, Min Kyung Hyun, Seung-Hyun Ko Journal of Medical Internet Research.2022; 24(7): e37430. CrossRef
A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim Diabetes, Obesity and Metabolism.2022; 24(9): 1800. CrossRef
Hypoglycemic agents and glycemic variability in individuals with type 2 diabetes: A systematic review and network meta-analysis SuA Oh, Sujata Purja, Hocheol Shin, Minji Kim, Eunyoung Kim Diabetes and Vascular Disease Research.2022; 19(3): 147916412211068. CrossRef
Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy Youngsook Kim, Ji Hye Huh, Minyoung Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee Frontiers in Endocrinology.2022;[Epub] CrossRef
Factors Influencing the Utilization of Diabetes Complication Tests Under the COVID-19 Pandemic: Machine Learning Approach Haewon Byeon Frontiers in Endocrinology.2022;[Epub] CrossRef
Association of prediabetes with death and diabetic complications in older adults: the pros and cons of active screening for prediabetes Giwoong Choi, Hojun Yoon, Hyun Ho Choi, Kyoung Hwa Ha, Dae Jung Kim Age and Ageing.2022;[Epub] CrossRef
Recent information on test utilization and intraindividual change in anti-glutamic acid decarboxylase antibody in Korea: a retrospective study Rihwa Choi, Wonseo Park, Gayoung Chun, Jiwon Lee, Sang Gon Lee, Eun Hee Lee BMJ Open Diabetes Research & Care.2022; 10(3): e002739. CrossRef
Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone? Eun-Jung Rhee Endocrinology and Metabolism.2022; 37(3): 415. CrossRef
Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents Kyung-Soo Kim The Journal of Korean Diabetes.2022; 23(2): 83. CrossRef
Maintaining Physical Activity Is Associated with Reduced Major Adverse Cardiovascular Events in People Newly Diagnosed with Diabetes Duhoe Kim, Jaehun Seo, Kyoung Hwa Ha, Dae Jung Kim Journal of Obesity & Metabolic Syndrome.2022; 31(2): 187. CrossRef
Effect of Carbohydrate-Restricted Diets and Intermittent Fasting on Obesity, Type 2 Diabetes Mellitus, and Hypertension Management: Consensus Statement of the Korean Society for the Study of Obesity, Korean Diabetes Association, and Korean Society of Hype Jong Han Choi, Yoon Jeong Cho, Hyun-Jin Kim, Seung-Hyun Ko, Suk Chon, Jee-Hyun Kang, Kyoung-Kon Kim, Eun Mi Kim, Hyun Jung Kim, Kee-Ho Song, Ga Eun Nam, Kwang Il Kim Journal of Obesity & Metabolic Syndrome.2022; 31(2): 100. CrossRef
Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus Jeongmin Lee, Jae-Seung Yun, Seung-Hyun Ko Nutrients.2022; 14(15): 3086. CrossRef
Severe hypoglycemia as a risk factor for cardiovascular outcomes in patients with type 2 diabetes: is it preventable? Seung-Hyun Ko Cardiovascular Prevention and Pharmacotherapy.2022; 4(3): 106. CrossRef
New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi Diabetes & Metabolism Journal.2022; 46(4): 517. CrossRef
Current status of obesity treatment in Korea: based on the 2020 Korean Society for the Study of Obesity guidelines for obesity management Eun-Jung Rhee Journal of the Korean Medical Association.2022; 65(7): 388. CrossRef
Experiences of Using Wearable Continuous Glucose Monitors in Adults With Diabetes: A Qualitative Descriptive Study Hee Sun Kang, Hyang Rang Park, Chun-Ja Kim, Savitri Singh-Carlson The Science of Diabetes Self-Management and Care.2022; 48(5): 362. CrossRef
젊은 2형 당뇨병 환자의 관리 재현 배 Public Health Weekly Report.2022; 15(35): 2474. CrossRef
Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease Jong Ha Baek, Ye Seul Yang, Seung-Hyun Ko, Kyung Do Han, Jae Hyeon Kim, Min Kyong Moon, Jong Suk Park, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Jong Han Choi, Kyu Yeon Hur Diabetes & Metabolism Journal.2022; 46(5): 701. CrossRef
Low-Density Lipoprotein Cholesterol Level, Statin Use and Myocardial Infarction Risk in Young Adults Heekyoung Jeong, Kyungdo Han, Soon Jib Yoo, Mee Kyoung Kim Journal of Lipid and Atherosclerosis.2022; 11(3): 288. CrossRef
Blood Pressure Target in Type 2 Diabetes Mellitus Hyun-Jin Kim, Kwang-il Kim Diabetes & Metabolism Journal.2022; 46(5): 667. CrossRef
Association of underweight status with the risk of tuberculosis: a nationwide population-based cohort study Su Hwan Cho, Hyun Lee, Hyuktae Kwon, Dong Wook Shin, Hee-Kyung Joh, Kyungdo Han, Jin Ho Park, Belong Cho Scientific Reports.2022;[Epub] CrossRef
Exploring the risk factors of impaired fasting glucose in middle-aged population living in South Korean communities by using categorical boosting machine Haewon Byeon Frontiers in Endocrinology.2022;[Epub] CrossRef
External validation and clinical application of the predictive model for severe hypoglycemia Jae-Seung Yun, Kyungdo Han, Soo-Yeon Choi, Seon-Ah Cha, Yu-Bae Ahn, Seung-Hyun Ko Frontiers in Endocrinology.2022;[Epub] CrossRef
Effect of Euonymus alatus Extracts on Diabetes Related Markers in Pancreatic β-Cells and C57BL/Ksj-db/db Mice Ye Rin Kim, Eun-young Kim, Seong Uk Lee, Young Wan Kim, Yoon Hee Kim Journal of the Korean Society of Food Science and Nutrition.2022; 51(9): 894. CrossRef
Muscle fat contents rather than muscle mass determines nonalcoholic steatohepatitis and liver fibrosis in patients with severe obesity Eugene Han, Mi Kyung Kim, Hye Won Lee, Seungwan Ryu, Hye Soon Kim, Byoung Kuk Jang, Youngsung Suh Obesity.2022; 30(12): 2440. CrossRef
Correlation between shift work and non-alcoholic fatty liver disease among male workers in the steel manufacturing company of Korea: a cross-sectional study Kiseok Kim, Yong-Jin Lee, Soon-Chan Kwon, Young-Sun Min, Hyun Kyo Lee, Gwangin Baek, Sang Hyeon Kim, Eun-Chul Jang Annals of Occupational and Environmental Medicine.2022;[Epub] CrossRef
FGM-based remote intervention for adults with type 1 diabetes: The FRIEND randomized clinical trial Jinju Lee, Myeong Hoon Lee, Jiyun Park, Kyung-Soo Kim, Soo-Kyung Kim, Yong-Wook Cho, Hyun Wook Han, Young Shin Song Frontiers in Endocrinology.2022;[Epub] CrossRef
Screening for Prediabetes and Diabetes in Korean Nonpregnant Adults: A Position Statement of the Korean Diabetes Association, 2022 Kyung Ae Lee, Dae Jung Kim, Kyungdo Han, Suk Chon, Min Kyong Moon Diabetes & Metabolism Journal.2022; 46(6): 819. CrossRef
Blood Pressure Control in Patients with Diabetic Kidney Disease Yaeni Kim, Won Kim, Jwa-Kyung Kim, Ju Young Moon, Samel Park, Cheol Whee Park, Hoon Suk Park, Sang Heon Song, Tae-Hyun Yoo, So-Young Lee, Eun Young Lee, Jeonghwan Lee, Kyubok Jin, Dae Ryong Cha, Jin Joo Cha, Sang Youb Han Electrolytes & Blood Pressure.2022; 20(2): 39. CrossRef
The Gangwon Obesity and Metabolic Syndrome Study: Methods and Initial Baseline Data Yoon Jeong Cho, Sohyun Park, Sung Soo Kim, Hyo Jin Park, Jang Won Son, Tae Kyung Lee, Sangmo Hong, Jee-Hyun Kang, Seon Mee Kim, Yang-Hyun Kim, Won Jun Kim, Young Eun Seo, Yoosuk An, Sang Youl Rhee, Suk Chon, Sookyoung Jeon, Kyungho Park, Bong-Soo Kim, Cha Journal of Obesity & Metabolic Syndrome.2022; 31(4): 303. CrossRef
Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? Hwi Seung Kim, Chang Hee Jung International Journal of Molecular Sciences.2021; 22(18): 9936. CrossRef
Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study Eu Jeong Ku, Dong-Hwa Lee, Hyun Jeong Jeon, Tae Keun Oh Diabetes Research and Clinical Practice.2021; 182: 109123. CrossRef
Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707) Mi-kyung Kim Diabetes & Metabolism Journal.2021; 45(6): 968. CrossRef
Incidence and Risk Factors for Progression to Diabetes Mellitus: A Retrospective Cohort Study Min Kyung Hyun, Jong Heon Park, Kyoung Hoon Kim, Soon-Ki Ahn, Seon Mi Ji International Journal of Environmental Research and Public Health.2021; 19(1): 123. CrossRef
2021 Clinical Practice Guidelines for Diabetes: Pharmacotherapy and the Korean Diabetes Association Support System Kyu Yeon Hur The Journal of Korean Diabetes.2021; 22(4): 250. CrossRef
2021 Clinical Practice Guidelines for Diabetes: Management of Cardiovascular Risk Min Kyong Moon The Journal of Korean Diabetes.2021; 22(4): 259. CrossRef
The effect of close and intensive therapeutic monitoring of patients with poorly controlled type 2 diabetes with different glycemic background Ayşe Naciye Erbakan, Müzeyyen Arslan Bahadir, Fatoş Nimet Kaya, Büşra Güleç, Miraç Vural Keskinler, Özge Faydaliel, Banu Mesçi, Aytekin Oğuz Medicine.2023; 102(50): e36680. CrossRef
Reduced macula microvascular densities may be an early indicator for diabetic peripheral neuropathy Xiaoyu Deng, Shiqi Wang, Yan Yang, Aizhen Chen, Jinger Lu, Jinkui Hao, Yufei Wu, Qinkang Lu Frontiers in Cell and Developmental Biology.2022;[Epub] CrossRef
Background Angiotensin-converting enzyme 2 facilitates the entry of severe acute respiratory syndrome coronavirus 2 into the human body. We investigated the association of renin-angiotensin-aldosterone system (RAAS) inhibitor use with severe coronavirus disease 2019 (COVID-19) outcomes in hypertensive patients.
Methods We identified hypertensive patients with confirmed COVID-19 from the Korean Health Insurance Review and Assessment Service from inception to May 15, 2020. The primary outcome was the composite of intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), continuous renal replacement therapy (CRRT), extracorporeal membrane oxygenation (ECMO), and death from COVID-19. The individual components were evaluated as secondary outcomes.
Results Of 1,374 hypertensive patients with COVID-19, 1,076 (78.3%) and 298 (21.7%) were users and never-users of RAAS inhibitors, respectively. The RAAS inhibitor users were not associated with the risk of the primary outcome (adjusted odds ratio [aOR], 0.72; 95% confidence interval [CI], 0.46 to 1.10). The risk of ICU admission was significantly lower in the users than the never-users (aOR, 0.44; 95% CI, 0.24 to 0.84). The RAAS inhibitors were beneficial only in ICU admissions that did not require IMV (aOR, 0.28; 95% CI, 0.14 to 0.58). The risk of death from COVID-19 was comparable between the groups (aOR, 1.09; 95% CI, 0.64 to 1.85). We could not evaluate the risks of CRRT and ECMO owing to the small number of events.
Conclusion RAAS inhibitor use was not associated with the composite of severe outcomes in the hypertensive patients with COVID-19 but significantly lowered the risk of ICU admission, particularly in patients who did not require IMV.
Citations
Citations to this article as recorded by
Systematic review and meta-analysis of the clinical outcomes of ACEI/ARB in East-Asian patients with COVID-19 Nancy Xurui Huang, Qi Yuan, Fang Fang, Bryan P. Yan, John E. Sanderson, Masaki Mogi PLOS ONE.2023; 18(1): e0280280. CrossRef
Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research Jordan Loader, Frances C. Taylor, Erik Lampa, Johan Sundström Journal of the American Heart Association.2022;[Epub] CrossRef
Renin-angiotensin-aldosterone system blockers in Bulgarian COVID-19 patients with or without chronic kidney disease Rumen Filev, Lionel Rostaing, Mila Lyubomirova, Boris Bogov, Krassimir Kalinov, Dobrin Svinarov Medicine.2022; 101(48): e31988. CrossRef